On the Record · Alnylam Pharmaceuticals
Alnylam Pharmaceuticals competitors, on the record
The companies Alnylam Pharmaceuticals names as competitors in its annual reports, 2023 to 2025, and the companies that name Alnylam Pharmaceuticals, each with the sentence and the filing.
Who Alnylam Pharmaceuticals names
| Company | Named in |
|---|---|
| BridgeBio | 2025 |
| Novo Nordisk | 2025 |
| Pfizer | 2025 |
In its own words
BridgeBio, Pfizer
Word for word“For example, AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy, competes with VYNDAQEL/VYNDAMAX (tafamidis), which is marketed by Pfizer, and ATTRUBY (acoramidis), which is marketed by BridgeBio, both of which are approved to treat ATTR amyloidosis with cardiomyopathy.” 10-K for 2025
Novo Nordisk
Word for word“We are aware of approved products and product candidates in various stages of clinical development for the treatment of PH1 that would compete with OXLUMO, our RNAi therapeutic approved in the U.S. and EU for the treatment of this disease, including Novo Nordisk’s RIVFLOZA (nedosiran), which was approved for the treatment of PH1 in September 2023 and launched in the U.S. in early 2024.” 10-K for 2025
Who names Alnylam Pharmaceuticals
Companies whose own annual reports name Alnylam Pharmaceuticals as a competitor.
Word for word“A number of companies, including some mid-to-large biopharmaceutical companies, such as Alnylam Pharmaceuticals, Bayer AG, Novo Nordisk, CSL Ltd., Pfizer Inc., Roche Holding AG, Sanofi Genzyme and Shire Plc., currently market or are pursuing the development of products for the treatment of hemophilia.” 10-K for 2017
Word for word“Tegsedi faces competition from drugs like Onpattro (patisiran) which was launched by Alnylam Pharmaceuticals in the United States in 2018 and received approval in Brazil for the treatment of hATTR amyloidosis in 2020 as was well as AMVUTTRA (vutrisiran) which Alnylam Pharmaceuticals received approval for in the United States and Brazil in 2022 for the treatment of the polyneuropathy of hATTR amyloidosis in adults.” 10-K for 2025
Read from Alnylam Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-12. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.